Multimeric Protein Toxins to Target Cells Having Multiple Identifying Characteristics


This technology relates to multimeric bacterial protein toxins which can be used to specifically target cells. Specifically, this is a modified recombinant anthrax toxin protective antigen (PrAg) that has been modified in several ways. First, the PrAg can be activated both by a metalloproteinase (MMP) and by urokinase plasminogen activator (uPA). Second, the native PrAg lethal factor (LF) binding site has been modified so that only a modified PrAg comprising two different monomers can bind anthrax LF. When administered with an effector component, the recombinant anthrax toxins are toxic only to cells expressing both a MMP and uPA on their surface. This technology is therefore useful for selective methods of treating cancers, because many cancer cells express multiple cell-surface proteases.

Inventors:

Stephen Leppla (NIAID)  ➽ more inventions...

Shihui Liu (NIAID)  ➽ more inventions...

Thomas Bugge (NIDCR)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 8,388,933 issued 2013-03-05
US Application No. PCT/US2005/04216
PCT Application No. 13/088,011

Collaboration Opportunity:

The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this invention. For collaboration opportunities, please contact Dr. Natalie Greco at Natalie.Greco@nih.gov or 301-761-7898.


Licensing Contact:
Michael Piziali,
Email: pizialim@niaid.nih.gov
Phone: 301-496-2644

OTT Reference No: E-059-2004-0
Updated: Jul 6, 2017